{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T09:58:33Z","timestamp":1791280713092,"version":"4.1.0"},"reference-count":23,"publisher":"Journal of Neurosurgery Publishing Group (JNSPG)","issue":"6","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JNS"],"published-print":{"date-parts":[[2011,6]]},"abstract":"\n Object<\/jats:title>\n Seizures occur in approximately 80% of patients with low-grade gliomas (LGGs). The majority of patients are treated with anticonvulsant monotherapy; however, many patients require multidrug therapy, or their seizures are refractory to antiepileptic drugs altogether. The oral alkylating agent temozolomide has emerged as a potential initial treatment option for LGG. A few reports suggest an association between temozolomide and reduced seizure frequency in patients with intractable epilepsy.<\/jats:p>\n <\/jats:sec>\n \n Methods<\/jats:title>\n Using their clinical database, the authors identified adult patients whose LGGs were treated using temozolomide as the initial antineoplastic therapy at the University of Virginia Health System. As a control group, the authors assessed patients whose LGGs were under observation. All patients had seizure disorders that were treated with anticonvulsants. Seizure frequency in patients with intractable epilepsy was analyzed before and after treatment with temozolomide. Age at diagnosis, sex, antiepileptic drugs, pathological subtype, surgical treatment, and follow-up until progression were also assessed. Interval seizure frequency was meticulously analyzed at each neurooncology clinic visit. A meaningful difference in seizures was defined as a reduction in seizure frequency of greater than 50% per month.<\/jats:p>\n <\/jats:sec>\n \n Results<\/jats:title>\n Thirty-nine patients were identified in the temozolomide cohort and 30 patients in the control cohort. The median age at diagnosis was 46 years for the former cohort and 41.5 years for the latter. The median length of follow-up was 39 months for the temozolomide group and 37 months for the control group. There was a significant difference in reduced seizure frequency between patients receiving temozolomide (59%) and those who did not receive temozolomide (13%, p < 0.001). Seven patients (18%) in the temozolomide group displayed this improvement independent of antiepileptic drug adjustment compared with no patient in the control group (p < 0.001).<\/jats:p>\n <\/jats:sec>\n \n Conclusions<\/jats:title>\n The authors' data suggest that a subset of patients with LGGs experience improvement in seizure frequency during treatment with temozolomide independent of antiepileptic drug adjustment. This decrease in seizure frequency appears independent of the natural history of seizures in patients whose tumors are under observation. Consequently, seizures in patients with LGGs may be better controlled with the combination of AEDs and temozolomide.<\/jats:p>\n <\/jats:sec>","DOI":"10.3171\/2010.12.jns101602","type":"journal-article","created":{"date-parts":[[2011,1,14]],"date-time":"2011-01-14T11:14:07Z","timestamp":1295003647000},"page":"1617-1621","source":"Crossref","is-referenced-by-count":89,"title":["Impact of temozolomide chemotherapy on seizure frequency in patients with low-grade gliomas"],"prefix":"10.3171","volume":"114","author":[{"given":"Jonathan H.","family":"Sherman","sequence":"first","affiliation":[{"name":"Departments of Neurological Surgery,"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Krisztina","family":"Moldovan","sequence":"additional","affiliation":[{"name":"University of Virginia School of Medicine, Charlottesville, Virginia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H. Kwang","family":"Yeoh","sequence":"additional","affiliation":[{"name":"Departments of Neurological Surgery,"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert M.","family":"Starke","sequence":"additional","affiliation":[{"name":"Departments of Neurological Surgery,"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nader","family":"Pouratian","sequence":"additional","affiliation":[{"name":"Departments of Neurological Surgery,"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark E.","family":"Shaffrey","sequence":"additional","affiliation":[{"name":"Departments of Neurological Surgery,"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Schiff","sequence":"additional","affiliation":[{"name":"Departments of Neurological Surgery,"},{"name":"Neurology, and"},{"name":"Medicine, University of Virginia Health System; and"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1754","reference":[{"key":"b1-jns101602","series-title":"J Neurosurg","first-page":"62","article-title":"Low-grade gliomas associated with intractable epilepsy: seizure outcome utilizing electrocorticography during tumor resection","volume":"79","author":"Berger","year":"1993"},{"key":"b2-jns101602","series-title":"Ann Oncol","first-page":"1715","article-title":"Phase II study of primary temozolomide chemotherapy in patients with WHO grade II gliomas","volume":"14","author":"Brada","year":"2003"},{"key":"b3-jns101602","series-title":"J Natl Cancer Inst","first-page":"1473","article-title":"Specific genetic predictors of chemotherapeutic response and survival in patients with anaplastic oligodendrogliomas","volume":"90","author":"Cairncross","year":"1998"},{"key":"b4-jns101602","series-title":"J Neurosurg","first-page":"10","article-title":"Recurrence and malignant degeneration after resection of adult hemispheric low-grade gliomas. Clinical article","volume":"112","author":"Chaichana","year":"2010"},{"key":"b5-jns101602","series-title":"Stereotact Funct Neurosurg","first-page":"169","article-title":"Effect of ionizing radiation on partial seizures attributable to malignant cerebral tumors","volume":"67","author":"Chalifoux","year":"1997"},{"key":"b6-jns101602","series-title":"J Neurosurg","first-page":"227","article-title":"Seizure characteristics and control following resection in 332 patients with low-grade gliomas","volume":"108","author":"Chang","year":"2008"},{"key":"b7-jns101602","series-title":"J Neurosurg","first-page":"209","article-title":"Changes in gamma-aminobutyric acid and somatostatin in epileptic cortex associated with low-grade gliomas","volume":"77","author":"Haglund","year":"1992"},{"key":"b8-jns101602","series-title":"Neurology","first-page":"212","article-title":"Epileptic seizures during follow-up of patients treated for primary brain tumors","volume":"65","author":"Hildebrand","year":"2005"},{"key":"b9-jns101602","series-title":"Cancer","first-page":"1937","article-title":"Low grade supratentorial astrocytomas. Management and prognostic factors","volume":"73","author":"Janny","year":"1994"},{"key":"b10-jns101602","series-title":"J Neurosurg","first-page":"735","article-title":"Low-grade hemispheric gliomas in adults: a critical review of extent of resection as a factor influencing outcome","volume":"95","author":"Keles","year":"2001"},{"key":"b11-jns101602","series-title":"Ann Neurol","first-page":"514","article-title":"Epilepsy in low-grade gliomas: the impact on cognitive function and quality of life","volume":"54","author":"Klein","year":"2003"},{"issue":"2","key":"b12-jns101602","series-title":"Neurosurg Focus","first-page":"E1","article-title":"Low-grade central nervous system tumors","volume":"12","author":"Lopes","year":"2002"},{"key":"b13-jns101602","series-title":"Epilepsia","first-page":"822","article-title":"The spectrum of long-term epilepsy-associated tumors: long-term seizure and tumor outcome and neurosurgical aspects","volume":"44","author":"Luyken","year":"2003"},{"key":"b14-jns101602","series-title":"Epilepsia","first-page":"1237","article-title":"Temozolomide treatment of refractory epilepsy in a patient with an oligodendroglioma","volume":"47","author":"Ngo","year":"2006"},{"key":"b15-jns101602","series-title":"Acta Neuropathol","first-page":"49","article-title":"Population-based study on incidence, survival rates, and genetic alterations of low-grade diffuse astrocytomas and oligodendrogliomas","volume":"108","author":"Okamoto","year":"2004"},{"key":"b16-jns101602","series-title":"Ann Oncol","first-page":"1722","article-title":"Temozolomide chemotherapy for progressive low-grade glioma: clinical benefits and radiological response","volume":"14","author":"Pace","year":"2003"},{"key":"b17-jns101602","series-title":"Epileptic Disord","first-page":"99","article-title":"Surgical pathology of drug-resistant partial epilepsy. A 10-year-experience with a series of 327 consecutive resections","volume":"4","author":"Pasquier","year":"2002"},{"key":"b18-jns101602","series-title":"Epilepsy: A Comprehensive Textbook","first-page":"2637","article-title":"Neoplastic diseases","volume":"3","author":"Recht","year":"2008"},{"key":"b19-jns101602","series-title":"Neurology","first-page":"1599","article-title":"Effect of cranial irradiation on seizure frequency in adults with low-grade astrocytoma and medically intractable epilepsy","volume":"43","author":"Rogers","year":"1993"},{"key":"b20-jns101602","series-title":"Neurology","first-page":"1366","article-title":"Outcome in adult low-grade glioma: the impact of prognostic factors and treatment","volume":"69","author":"Schiff","year":"2007"},{"key":"b21-jns101602","series-title":"Lancet","first-page":"985","article-title":"Long-term efficacy of early versus delayed radiotherapy for low-grade astrocytoma and oligodendroglioma in adults: the EORTC 22845 randomised trial","volume":"366","author":"van den Bent","year":"2005"},{"key":"b22-jns101602","series-title":"J Neurol Neurosurg Psychiatry","first-page":"581","article-title":"Supratentorial low grade astrocytoma: prognostic factors, dedifferentiation, and the issue of early versus late surgery","volume":"64","author":"van Veelen","year":"1998"},{"key":"b23-jns101602","series-title":"Expert Rev Anticancer Ther","first-page":"663","article-title":"Seizures in low- and high-grade gliomas: current management and future outlook","volume":"10","author":"Vecht","year":"2010"}],"container-title":["Journal of Neurosurgery"],"original-title":[],"link":[{"URL":"https:\/\/thejns.org\/view\/journals\/j-neurosurg\/114\/6\/article-p1617.xml","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/thejns.org\/downloadpdf\/journals\/j-neurosurg\/114\/6\/article-p1617.xml","content-type":"text\/html","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/thejns.org\/downloadpdf\/journals\/j-neurosurg\/114\/6\/article-p1617.xml","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,3,27]],"date-time":"2023-03-27T01:22:50Z","timestamp":1679880170000},"score":1,"resource":{"primary":{"URL":"https:\/\/thejns.org\/view\/journals\/j-neurosurg\/114\/6\/article-p1617.xml"}},"subtitle":["Clinical article"],"short-title":[],"issued":{"date-parts":[[2011,6]]},"references-count":23,"journal-issue":{"issue":"6"},"URL":"https:\/\/doi.org\/10.3171\/2010.12.jns101602","relation":{"has-review":[{"id-type":"doi","id":"10.3410\/f.10787957.11700054","asserted-by":"object"}]},"ISSN":["0022-3085","1933-0693"],"issn-type":[{"value":"0022-3085","type":"print"},{"value":"1933-0693","type":"electronic"}],"subject":[],"published":{"date-parts":[[2011,6]]}}}